Mounjaro Matches Trulicity in Cardiovascular Trial

Eli Lilly's diabetes drug Mounjaro demonstrated non-inferiority to the older drug Trulicity in a multinational trial of over 13,000 adults with type 2 diabetes and established cardiovascular disease. The trial showed Mounjaro reduced major adverse cardiovascular events by 8% compared to Trulicity, but this difference did not reach statistical superiority on the primary endpoint. However, Mounjaro achieved a 16% lower all-cause mortality rate and showed greater improvements in A1C, weight loss, and kidney function. Analysts view the results as sufficient to support Mounjaro's continued market growth, especially as Trulicity approaches patent expiration. Some clinicians highlight the clinical significance of the mortality benefit, while others note that the lack of statistical superiority may moderate enthusiasm. Eli Lilly plans to seek expanded FDA approval for Mounjaro based on these findings.